Publicacións (54) Publicacións de Rosa María Fernández Torres

2022

  1. Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

    Dermatology and Therapy, Vol. 12, Núm. 3, pp. 761-770

  2. New Epidemiological Outcomes in Anthropophilic tinea capitis, a Case Series Study in Northwestern Spain

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 1, pp. T74-T77

  3. New Epidemiological Outcomes in Anthropophilic tinea capitis, a Case Series Study in Northwestern Spain

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 1, pp. 74-77

  4. Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis

    Frontiers in Medicine, Vol. 9

2020

  1. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital

    Journal of Dermatological Treatment, Vol. 31, Núm. 7, pp. 698-701

2019

  1. Atopic dermatitis school: The importance of training for caregivers

    Piel, Vol. 34, Núm. 7, pp. 390-395

2018

  1. Lupus eritematoso

    Manual de dermatología (Grupo Aula Médica S.L.), pp. 340-357

  2. Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 8, pp. 722-732

2016

  1. Apremilast en dermatología

    Piel, Vol. 31, Núm. 3, pp. 206-215

  2. Manifestaciones cutáneas de las enfermedades sistémicas en pediatría

    Pediatria Integral

  3. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value

    International Journal of Clinical Pharmacy, Vol. 38, Núm. 5, pp. 1142-1148

2015

  1. Actualización en displasia ectodérmica hipohidrótica

    Piel

  2. Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: The ACTUO observational prospective multicenter cohort trial in 643 patients

    BMC Dermatology, Vol. 15, Núm. 1

  3. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

    Journal of Dermatological Treatment, Vol. 26, Núm. 3, pp. 217-222

  4. Infliximab drug and antibody levels in patients with dermatological conditions

    International Journal of Clinical Pharmacy, Vol. 37, Núm. 2, pp. 320-326

  5. Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice

    Value in Health, Vol. 18, Núm. 8, pp. 1158-1161

  6. Teledermatology: Diagnostic reliability in 383 children

    European Journal of Dermatology, Vol. 25, Núm. 6, pp. 563-569

2014

  1. Anomalías de la pigmentación

    Tratado de pediatría (Editorial Médica Panamericana), pp. 2416-2422

  2. Guías para el tratamiento de la psoriasis en placas moderada-grave con terapias biológicas

    Terapias biológicas para la psoriasis (Fundación do Complexo Hospitalario Universitario A Coruña), pp. 7

  3. Long-term response to etanercept monotherapy in moderate to severe psoriasis: Assessment in daily practice by the maintenance of low values of PASI and BSA

    Journal of Dermatological Treatment, Vol. 25, Núm. 1, pp. 54-56